Aclaris ATI-052 Shows 45% Placebo-Adjusted EASI Change at Day 57
Aclaris Therapeutics said ATI-052 showed a 45% placebo-adjusted mean change in EASI score at day 57 in an atopic dermatitis trial.
Related stories
Enerflex Shares Rise After Q3 Earnings Beat, Dividend Hike; Revenue Misses
Enerflex shares rose in early Thursday trading after its third-quarter earnings beat and dividend hike, while revenue missed.
M impact | EQUITY | Oct 29, 2026, 01:46 PM UTC
Wesco International Shares Pare Gains; Last Up 3.5%
M impact | EQUITY | Oct 29, 2026, 01:45 PM UTC
NextDecade Shares Rise More Than 9% After Q3 Earnings Swing
NextDecade shares were up more than 9% early Thursday amid a swing to third-quarter earnings.
M impact | EQUITY | Oct 29, 2026, 01:45 PM UTC
L3Harris shares pare gains, still up 4.1%
M impact | EQUITY | Oct 29, 2026, 01:45 PM UTC
Intercontinental Exchange Q3 Revenue Rises 16.1% to $2.8 Billion
Intercontinental Exchange reported Q3 2026 revenue of $2.8 billion, up 16.1% year on year and above market expectations. Non-GAAP profit was $2.02 per share, 2.5% above analysts’ c
M impact | EQUITY | Oct 29, 2026, 01:45 PM UTC
Middle East Holding Reports Q3 Revenue of 761,229 Dinars
M impact | EQUITY | Oct 29, 2026, 01:45 PM UTC